The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Everolimus and sunitinib as first- and second-line treatments of patients with metastatic papillary renal cell carcinoma (pRCC): A retrospective study of the GETUG (Groupe Français d’Etude des Tumeurs Uro-Génitales).
 
Claude Linassier
Honoraria - Bayer; Ipsen; Novartis; Sanofi
Research Funding - Novartis (Inst)
 
Laurence Albiges
No Relationships to Disclose
 
Christine Chevreau
Honoraria - Bristol-Myers Squibb; Merck Serono; Novartis; Pfizer
 
Brigitte Laguerre
No Relationships to Disclose
 
Stephane Oudard
Honoraria - Bayer; Bristol-Myers Squibb; Novartis; Pfizer
 
Marine Gross-Goupil
No Relationships to Disclose
 
Gwenaelle Gravis
No Relationships to Disclose
 
Francois Goldwasser
No Relationships to Disclose
 
Frederic Rolland
No Relationships to Disclose
 
Remy Delva
No Relationships to Disclose
 
Laura Moise
No Relationships to Disclose
 
Jean-Marc Tourani
No Relationships to Disclose
 
Cecile Vassal
No Relationships to Disclose
 
Sylvie Zanetta
No Relationships to Disclose
 
Nicolas Penel
No Relationships to Disclose
 
Aude Flechon
Honoraria - GlaxoSmithKline; Novartis; Pfizer
Travel, Accommodations, Expenses - Novartis; Pfizer
 
Christine Theodore
No Relationships to Disclose
 
Philippe Barthelemy
No Relationships to Disclose
 
Carolina Saldana
No Relationships to Disclose
 
Bernard Escudier
No Relationships to Disclose